
About Denovo Biopharma
Denovo Biopharma is a Healthcare company based in San Diego (United States) founded in 2013. Genomic biomarker discovery platform is developed for drug personalization. Denovo Biopharma has raised $171.82 million across 4 funding rounds from investors including CICC, Qcc and CITIC. The company has 42 employees. Its focus areas include Life Sciences, Genomics, Genomics Research and Biomarker Discovery. Its legal entity is DENOVO BIOPHARMA LLC. Its competitors include Metabolon, Avidity Biosciences and Sutro Biopharma; 3 of its 3 listed competitors have raised funding.
Company details
Denovo Biopharma was founded in 2013 and is based in San Diego, United States. The company operates in the biopharmaceutical sector, where a genomic biomarker discovery platform is utilized to identify biomarkers for personalized drug development. This approach is applied across multiple therapeutic areas, including oncology, metabolic disorders, cardiology, immunology, and neurology, supporting targeted therapies in clinical applications.
- Headquarters San Diego, United States
- Employees 42
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website denovobiopharma.com
- Social LinkedIn
- Legal Name Denovo Biopharma Llc
- Total Equity Funding$171.82M (USD)
in 4 rounds
- Latest Funding Round$45.9M (USD), Series D
Dec 2020
- InvestorsCICC
& 13 more
- Employee Count42
Funding Insights of Denovo Biopharma
Denovo Biopharma has successfully raised a total of $171.82M across 4 strategic funding rounds. The most recent funding activity was a Series D round of $45.9 million completed in December 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $171.82M
- Total Rounds 4
- Last Round Series D β $45.9M
- Investors Count 14
All 4 funding rounds of Denovo Biopharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2020 | $45.9M | Series D | β | Yingke Capital | β |
| Jun 2020 | $83.32M | Series C | β | CICC | |
| Oct 2019 | $42.6M | Series B | β | Jiuyou Fund, Share Capital | β |
| Jul 2015 | Series A | β | Zhejiang Xianju Pharmaceutical, Guangzhou Yuexiu Industrial Investment Fund Management | β |
14 investors in total: 14 institutional.
Investors in Denovo Biopharma
Denovo Biopharma has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include CICC, Qcc and CITIC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A venture capital firm based in Shenzhen, China, is operated. | sharecapital.cn | Shenzhen, China | ||
Investment bank & PE fund focused on multiple sectors | jiuyoucapital.com.cn | |||
A venture capital firm focused on life sciences investments. | sangelvc.com | Shenzhen, China | ||
| gzvcm.com | ||||
Yuexiu Capital is engaged in financial services and asset management. | yuexiufund.com | Guangzhou, China | ||
Private equity investments in China are handled by Goldstone Investment. | goldstone-investment.com | Beijing, China | ||
Operates as an investment advisory firm providing expert guidance. | 2010 | yingkepe.com | Fuzhou, China | |
Diversified asset management and corporate advisory services are provided. | 1995 | cicc.com | Beijing, China | |
Provider of investment, wealth & asset management services | 1995 | cs.ecitic.com | Beijing, China | |
Jiuyou Fund is engaged in investment management and financial services. | jiuyoufund.com | Shanghai, China |
Investor details for Denovo Biopharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Denovo Biopharma
20 people are tracked at Denovo Biopharma (13 in leadership, 6 in board & advisors, 1 in team); the tracked headcount is 42.
| Name | Role | Group |
|---|---|---|
Sina Burrell | Head of Quality Assurance | Leadership |
Carrie Chen | Chief Financial Officer | Leadership |
Martin Mumenthaler | Sr. Director, Clinical Sciences | Leadership |
Michael Haller | Chief Business Officer And Head Of US Finance | Leadership |
Wen Luo | CEO & CSO | Leadership |
Xiangming Fang | Chief Operating Officer | Leadership |
Yu Sun | Director Of Finance And Accounting | Leadership |
Xiao-Xiong Lu | Chief Technical Officer | Leadership |
Sudhir Borgonha, MD | Vice President, Clinical Development (Oncology) | Leadership |
Holly Huang, PhD, MPH | Vice President and Head of Biometrics | Leadership |
Julie Doostzadeh | Executive Director of Clinical Operations | Leadership |
Crystal Chen | Vp, CNS Clinical Development | Leadership |
Anupam Agarwal, MD, MPH | Senior Vice President, Global Head of Drug Safety & PV | Leadership |
K. Peter Hirth | Advisors | Board & advisors |
Steven Leventer | Advisor | Board & advisors |
John M. Davis | Advisor | Board & advisors |
Jeremy Barton | Advisor | Board & advisors |
Robert Alexander | Advisor | Board & advisors |
W. K. Alfred Yung | Advisor | Board & advisors |
Larry D. Alphs | SVP, CNS Clinical Development | Team |
Complete people profiles for Denovo Biopharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Denovo Biopharma
3 dated milestones of Denovo Biopharma across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Denovo Biopharma is founded.
- Funding First funding round.
- Funding Latest funding round, Series D, of $45.9M.
Competitors of Denovo Biopharma
Denovo Biopharma has 3 listed competitors in our database, 3 of them funded. They include Metabolon, Avidity Biosciences and Sutro Biopharma.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| metabolon.com | 2000 | Morrisville, United States | $165.87M | 189 | Solutions for biomarker discovery and diagnostic testing are provided. | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. |
Detailed competitors of Denovo Biopharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Denovo Biopharma
The website of Denovo Biopharma (denovobiopharma.com) receives about 1.7K visits a month.
- Monthly visits1.7K
▲ 16% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Denovo Biopharma (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Denovo Biopharma
Complete news archive for Denovo Biopharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Denovo Biopharma
Denovo Biopharma was founded in 2013 and raised its 1st funding round 2 years after it was founded.
Denovo Biopharma is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Denovo Biopharma is a funded company, having raised a total of $171.82M across 4 funding rounds to date.
Denovo Biopharma has 42 employees.
Denovo Biopharma was founded in 2013 and is based in San Diego, United States. The company operates in the biopharmaceutical sector, where a genomic biomarker discovery platform is utilized to identify biomarkers for personalized drug development. This approach is applied across multiple therapeutic areas, including oncology, metabolic disorders, cardiology, immunology, and neurology, supporting targeted therapies in clinical applications.
Denovo Biopharma's top competitors include Sutro Biopharma, Avidity Biosciences and Metabolon.
Denovo Biopharma has 14 investors. Key investors include CICC, Qcc, CITIC, Zhejiang Xianju Pharmaceutical, and Yingke Capital.
Denovo Biopharma operates through Denovo Biopharma Llc.
